ClinicalTrials.gg
CompletedNCT01855750Updated Feb 4, 2025Results posted

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

A Phase 3 interventional study of Ibrutinib and Placebo in Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 205 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's title name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
838
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 10 under way, 2 of them phase 3. ibrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
Largest of 26
838 · median 44
Started
2013
with 2 others
Phase 3
3 of 26
none open now
Registered
4th of 26
by date
Lead sponsor
2 of 26
Janssen Research & Development, LLC

Among the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, this one has the largest enrollment, is one of 3 that started in 2013, is one of 3 in phase 3, and was the 4th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene expression profiling (GEP) or both populations.

Read the detailed description

This is a randomized (individuals assigned to study treatment by chance), double-blind (individuals and study personnel will not know the identity of study treatments), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to compare the efficacy and safety of ibrutinib in combination with R-CHOP versus R-CHOP alone in adult patients newly diagnosed non-GCB DLBCL selected by IHC or newly diagnosed patients with ABC subtype of DLBCL identified by GEP or both populations. The study will include screening, active treatment, and posttreatment follow-up phases. The study will end when 50% of participants have died or 5 years after the last participant is randomized or the sponsor terminates the study, whichever occurs first. Approximately 800 participants will be randomly assigned in a 1:1 ratio to receive either placebo+R-CHOP (treatment arm A) or ibrutinib+R-CHOP (treatment arm B). All participants will receive R-CHOP as background therapy for 6 or 8 cycles (21 days per cycle) prespecified according to local practice. After 4 treatment cycles, an interim response assessment will be performed to evaluate disease progression for each participant. Participants with progressive disease or relapsed disease after complete response will be discontinued from treatment. Participants who discontinue R-CHOP without disease progression will continue study drug (placebo or ibrutinib) until 6 or 8 cycles are completed, disease progression, or unacceptable toxicity, whichever occurs first. After completion of study drug, participants will undergo assessment of tumor response based on the Revised Response Criteria for Malignant Lymphoma. Participants with documented residual disease upon completion of at least 6 cycles of R-CHOP therapy are considered eligible to initiate subsequent antilymphoma therapy. Serial pharmacokinetic samples will be collected before and after dosing, and safety will be monitored throughout the study.

03

Conditions studied

  • Lymphoma

Browse trials for

Keywords

  • Lymphoma
  • B-cell lymphoma
  • Non-germinal center B-cell subtype
  • Diffuse large B-cell lymphoma
  • Bruton's tyrosine kinase inhibitor
  • PCI-32765
  • JNJ-54179060
  • Ibrutinib
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's enrollment of 838 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No prior treatment for diffuse B-cell lymphoma (DLBCL)
  • -confirmed non-germinal center B-cell subtype DLBCL
  • Stage II (not candidates for local x-ray therapy), III, or IV disease by the Ann Arbor Classification
  • At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
  • Revised International Prognostic Index score of >=1
  • performance status grade of 0, 1, or 2
  • Hematology and biochemical laboratory values within protocol-defined parameters prior to random assignment and at baseline
  • within institutional normal limits, as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan
  • Agrees to protocol-defined use of effective (for women, these restrictions apply for 12 months after the last dose of rituximab or 1 month after the last dose of study drug, whichever is later; for men, these restrictions apply for 12 months after the last dose of rituximab or 3 months after the last dose of study drug, whichever is later)
  • Men must agree to not donate sperm during and after the study for 12 months after the last dose of rituximab or 3 months after the last dose of study drug, whichever is later
  • Women of must have a negative serum or urine pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 4 weeks of random assignment
  • Known central nervous system or primary mediastinal lymphoma
  • Prior history of indolent lymphoma
  • Diagnosed or treated for other than DLBCL, except: malignancy treated with curative intent and with no known active disease present for >=3 years before random assignment; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated carcinoma in situ without evidence of disease
  • History of stroke or intracranial hemorrhage within 6 months prior to random assignment
  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists
  • Requires treatment with strong inhibitors
  • Prior anthracycline use >=150 mg/m2
  • cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the Functional Classification
  • Known history of or active virus or active virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
  • Women who are pregnant or breastfeeding
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
838 participants (actual)

Study arms

  • Placebo comparator
    Treatment Arm A: placebo + R-CHOP

    Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)

    Drug: Placebo · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone (or equivalent)

  • Experimental
    Treatment Arm B: ibrutinib + R-CHOP

    Treatment Arm B = ibrutinib + R-CHOP

    Drug: Ibrutinib · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone (or equivalent)

Interventions

  • 560 mg capsules administered by mouth once daily (21-day cycles)

  • DrugPlacebo

    4 matched capsules administered by mouth once daily (21-day cycles)

  • 375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

  • 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

  • 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

  • 1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

  • 100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle

07

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population

    EFS: duration from randomization date to disease progression(PD) date, relapse from complete response(CR) assessed by investigator, initiation of subsequent systemic antilymphoma therapy for either positron emission tomography(PET)-positive/ biopsy-proven residual disease upon completion of \>=6 cycles of R-CHOP therapy/death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. PD: any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in sum of product of diameters(SPD) of \>1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

    Time frame: Up to 5.5 years

  2. Event-Free Survival (EFS) - Activated B-Cell (ABC) Population

    EFS: duration from randomization date to PD date, relapse from CR assessed by investigator, initiation of subsequent systemic antilymphoma therapy for either PET-positive/ biopsy-proven residual disease upon completion of \>=6 cycles of R-CHOP therapy/death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. PD: any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in SPD of \>1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

    Time frame: Up to approximately 4.5 years

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. Progressive Disease (PD): any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 centimeter (cm) in any axis, 50% increase in SPD of \>1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

    Time frame: Up to approximately 4.5 years

  2. Percentage of Participants Who Achieved Complete Response (CR)

    Percentage of participants with measurable disease who achieved CR were reported. CR: disappearance of all evidence of disease. CR Criteria: Complete disappearance of all disease-related symptoms; all lymph nodes and nodal masses regressed to normal size (less than or equal to \[\<=\]1.5 cm in greatest transverse diameter \[GTD\] for nodes greater than \[\>\]1.5 cm before therapy). Previous nodes of 1.1 to 1.5 cm in long axis and greater than (\>)1.0 cm in short axis before treatment decreased to \<=1.0 cm in short axis after treatment. Disappearance of all splenic and hepatic nodules and other extranodal disease; a negative positron emission tomography (PET) scan. A posttreatment residual mass of any size but PET-negative; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

    Time frame: Up to approximately 4.5 years

  3. Overall Survival

    Overall survival was defined as the duration from the date of randomization to the date of the participant's death. Median Overall Survival was estimated by using the Kaplan-Meier method.

    Time frame: Up to 5.5 years

  4. Time to Worsening in the Lymphoma Subscale of Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)

    Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.

    Time frame: Up to approximately 4.5 years

08

Results

Posted Mar 19, 2019
Limitations and caveats
Sponsor decided to stop the study as all participants had concluded study treatment and outcomes were not expected to change and study was considered as completed.

Participant flow

Participant flow — Overall Study
MilestoneTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
Started419419
Treated416418
Completed00
Not completed419419
Withdrew: Death7878
Withdrew: Lost to follow-up923
Withdrew: Withdrawal by subject3528
Withdrew: Sponsor ends the study297290

Outcome measures

PrimaryEvent-Free Survival (EFS) - Intent-to-Treat (ITT) Population

EFS: duration from randomization date to disease progression(PD) date, relapse from complete response(CR) assessed by investigator, initiation of subsequent systemic antilymphoma therapy for either positron emission tomography(PET)-positive/ biopsy-proven residual disease upon completion of \>=6 cycles of R-CHOP therapy/death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. PD: any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in sum of product of diameters(SPD) of \>1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

Time frame:
Up to 5.5 years
Reported as:
Median · Months
Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population
MonthsTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population49.64 (47.47 to NA)54.77 (48.16 to 54.77)
Statistical analysis
  • Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP · Log Rank · p = 0.5167 · Hazard ratio (hr): 0.922 · 95% CI 0.720 to 1.180
PrimaryEvent-Free Survival (EFS) - Activated B-Cell (ABC) Population

EFS: duration from randomization date to PD date, relapse from CR assessed by investigator, initiation of subsequent systemic antilymphoma therapy for either PET-positive/ biopsy-proven residual disease upon completion of \>=6 cycles of R-CHOP therapy/death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. PD: any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 cm in any axis, 50% increase in SPD of \>1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · Months
Event-Free Survival (EFS) - Activated B-Cell (ABC) Population
MonthsTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
Event-Free Survival (EFS) - Activated B-Cell (ABC) Population48.56 (48.56 to NA)48.16 (48.16 to NA)
Statistical analysis
  • Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP · Log Rank · p = 0.7311 · Hazard ratio (hr): 0.949 · 95% CI 0.704 to 1.279
SecondaryProgression-Free Survival (PFS)

PFS was defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first. Responses were based on Revised Response Criteria for Malignant Lymphoma. Progressive Disease (PD): any new lesion or increase by 50% of previously involved sites from nadir; PD criteria: Appearance of new nodal lesion 1.5 centimeter (cm) in any axis, 50% increase in SPD of \>1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis. CR: disappearance of all evidence of disease; CR criteria: nodal masses PET positive prior to therapy; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
Progression-Free Survival (PFS)48.56 (48.56 to NA)NA (48.16 to NA)
Statistical analysis
  • Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP · Log Rank · p = 0.5027 · Hazard ratio (hr): 0.917 · 95% CI 0.710 to 1.183
SecondaryPercentage of Participants Who Achieved Complete Response (CR)

Percentage of participants with measurable disease who achieved CR were reported. CR: disappearance of all evidence of disease. CR Criteria: Complete disappearance of all disease-related symptoms; all lymph nodes and nodal masses regressed to normal size (less than or equal to \[\<=\]1.5 cm in greatest transverse diameter \[GTD\] for nodes greater than \[\>\]1.5 cm before therapy). Previous nodes of 1.1 to 1.5 cm in long axis and greater than (\>)1.0 cm in short axis before treatment decreased to \<=1.0 cm in short axis after treatment. Disappearance of all splenic and hepatic nodules and other extranodal disease; a negative positron emission tomography (PET) scan. A posttreatment residual mass of any size but PET-negative; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

Time frame:
Up to approximately 4.5 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Complete Response (CR)
Percentage of participantsTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
Percentage of Participants Who Achieved Complete Response (CR)67.368.0
Statistical analysis
  • Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP · Cochran-Mantel-Haenszel (CMH) Chi-square · p = 0.8229 · Odds ratio (or): 0.967 · 95% CI 0.722 to 1.296
SecondaryOverall Survival

Overall survival was defined as the duration from the date of randomization to the date of the participant's death. Median Overall Survival was estimated by using the Kaplan-Meier method.

Time frame:
Up to 5.5 years
Reported as:
Median · Months
Overall Survival
MonthsTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
Overall SurvivalNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP · Log Rank · p = 0.8549 · Hazard ratio (hr): 1.030 · 95% CI 0.754 to 1.407
SecondaryTime to Worsening in the Lymphoma Subscale of Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)

Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score is the total of reverse scores, range 0 to 60. Higher scores indicate a better quality of life.

Time frame:
Up to approximately 4.5 years
Reported as:
Median · Months
Time to Worsening in the Lymphoma Subscale of Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)
MonthsTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
Time to Worsening in the Lymphoma Subscale of Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)11.7 (4.9 to 23.5)35.0 (19.8 to NA)
Statistical analysis
  • Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP · Log Rank · p = 0.0021 · Hazard ratio (hr): 1.358 · 95% CI 1.115 to 1.654

Adverse events

Collected over Up to 5.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm B: Ibrutinib+R-CHOP78/416 (18.8%)221/416 (53.1%)411/416 (98.8%)
Treatment Arm A: Placebo+R-CHOP78/418 (18.7%)143/418 (34.2%)411/418 (98.3%)
Most frequent serious events
Showing 10 of 227
Most frequent serious events
EventTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
Febrile NeutropeniaBlood and lymphatic system disorders78/41644/418
PneumoniaInfections and infestations28/41614/418
NeutropeniaBlood and lymphatic system disorders17/41613/418
AnaemiaBlood and lymphatic system disorders15/4165/418
DiarrhoeaGastrointestinal disorders15/4164/418
Lung InfectionInfections and infestations14/4167/418
Atrial FibrillationCardiac disorders13/4162/418
PyrexiaGeneral disorders12/41611/418
ThrombocytopeniaBlood and lymphatic system disorders9/4161/418
VomitingGastrointestinal disorders8/4162/418
Most frequent other events
Showing 10 of 56
Most frequent other events
EventTreatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOP
NeutropeniaBlood and lymphatic system disorders213/416248/418
AnaemiaBlood and lymphatic system disorders173/416116/418
NauseaGastrointestinal disorders170/416135/418
DiarrhoeaGastrointestinal disorders149/41681/418
FatigueGeneral disorders138/416102/418
ConstipationGastrointestinal disorders111/416110/418
White Blood Cell Count DecreasedInvestigations107/416104/418
AlopeciaSkin and subcutaneous tissue disorders69/416106/418
ThrombocytopeniaBlood and lymphatic system disorders102/41653/418
Neutrophil Count DecreasedInvestigations99/41681/418

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOPTotal
Mean61.1 ± 12.5758.8 ± 13.5759.9 ± 13.12
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOPTotal
Female198193391
Male221226447
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOPTotal
Hispanic or Latino171330
Not Hispanic or Latino388396784
Unknown or Not Reported141024
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOPTotal
White237250487
Black or African American448
Asian166160326
American Indian or Alaska Native213
Native Hawaiian or Other Pacific Islander000
Other112
Unknown000
Not reported729
Multiple213
Region of Enrollment
Region of Enrollment(Participants)Treatment Arm B: Ibrutinib+R-CHOPTreatment Arm A: Placebo+R-CHOPTotal
Argentina112
Australia12820
Belgium8715
Brazil8412
Canada12921
China10496200
Czech Republic181230
Denmark5611
Finland6814
France7411
Germany5813
Hungary5611
Israel111223
Italy241842
Japan334073
Mexico213
Netherlands516
Norway167
Poland152439
Russia193453
Korea, Republic Of141125
Spain5712
Sweden011
Taiwan, Province Of China8917
Turkey272451
Ukraine10919
United Kingdom141731
United States403676
09

Study locations

205 sites
  • Tucson, Arizona, United States
  • Greenbrae, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Salinas, California, United States
  • Stanford, California, United States
  • Danbury, Connecticut, United States
  • Hartford, Connecticut, United States
  • Washington, District of Columbia, United States
  • Atlanta, Georgia, United States
  • Marietta, Georgia, United States
  • Peoria, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Goshen, Indiana, United States
  • Indianapolis, Indiana, United States
  • Topeka, Kansas, United States
  • Louisville, Kentucky, United States
  • Baton Rouge, Louisiana, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Hackensack, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Bronx, New York, United States
  • Fresh Meadows, New York, United States
  • Johnson City, New York, United States
  • Mineola, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Charlotte, North Carolina, United States
  • Greenville, North Carolina, United States
  • Hickory, North Carolina, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • North Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Temple, Texas, United States
  • Burlington, Vermont, United States
  • Seattle, Washington, United States
  • Buenos Aires, Argentina
  • Ciudad Autonoma de Buenos Aires, Argentina
  • Ciudad de Buenos Aires, Argentina
  • Adelaide, Australia
  • Concord, Australia
  • Darlinghurst, Australia
  • Hobart, Australia
  • Melbourne, Australia
  • Nedlands, Australia
  • Perth, Australia
  • Randwick, Australia
  • South Brisbane, Australia
  • Woolloongabba, Australia
  • Antwerpen, Belgium
  • Brugge, Belgium
  • Brussel, Belgium
  • Gent, Belgium
  • Haine Saint Paul La Louviere, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Porto Alegre, Brazil
  • Rio De Janeiro, Brazil
  • Sao Paulo, Brazil
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Halifax, Nova Scotia, Canada
  • Toronto, Ontario, Canada
  • Levis, Quebec, Canada
  • Montreal, Quebec, Canada
  • Montréal, Quebec, Canada
  • Beijing, China
  • Changchun, China
  • Chengdu, China
  • Guangzhou, China
  • Hangzhou, China
  • Harbin, China
  • Jinan, China
  • Nanjing, China
  • Shanghai, China
  • Tianjin, China
  • Brno, Czechia
  • Hradec Kralove, Czechia
  • Ostrava, Czechia
  • Praha 10, Czechia
  • Praha 2, Czechia
  • Aarhus N., Denmark
  • Copenhagen, Denmark
  • Roskilde, Denmark
  • Vejle, Denmark
  • Helsinki, Finland
  • Jyväskylä, Finland
  • Oulu, Finland
  • Turku, Finland
  • Grenoble Cedex 9, France
  • Limoges, France
  • Paris, France

Showing the first 100 of 205 sites across 27 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, Vermeulen J, Shreeve M, Staudt LM. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021 Dec 13;39(12):1643-1653.e3. doi: 10.1016/j.ccell.2021.10.006. Epub 2021 Nov 4. PubMed 34739844 ↗
  • Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppa S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Duhrsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22. PubMed 30901302 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Feb 2018, 53 months.

Results were first posted in Mar 2019, 1 year after primary completion.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 53 months is close to that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2013
First posted
May 16, 2013
StartActual
Sep 3, 2013
Primary completionActual
Feb 26, 2018
CompletionActual
Apr 5, 2019
Results first posted
Mar 19, 2019
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01855750
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
May 16, 2013
Start date
Sep 3, 2013
Primary completion
Feb 26, 2018
Completion
Apr 5, 2019
Results posted
Mar 19, 2019
Last update
Feb 4, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion